Vir Biotechnology: Hep B And Cancer Projects March On

Group 1 - Vir Biotechnology (NASDAQ: VIR) experienced a significant rally in share price earlier in the year, leading to optimism despite associated risks [1] - The company operates in the biotech sector, focusing on the science behind its business and clinical trials [1] Group 2 - The article emphasizes the importance of due diligence in biotech investments to avoid potential pitfalls [1]